CClinicalTrials.gg
CompletedNCT07367386Updated Jan 27, 2026

Impact of Increasing BMI on the Success of Neuraxial Blocks in Class III Obese Parturients

An observational study in Neuraxial Blocks, sponsored by Mariah Arif. Completed at 1 site in Qatar. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-27.

Sponsored by Mariah Arif · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
1,917
Ages
18 Years and older
Sex
Female
01

Study summary

This study seeks to compare the success rates, feto-maternal outcomes, and complications associated with different neuraxial blocks in Class III obese parturient undergoing cesarean section

Read the detailed description

This was a retrospective cohort study. The data was obtained from electronic medical records of the eligible participants.

02

Conditions studied

  • Neuraxial Blocks

Browse trials for

Keywords

  • Neuraxial blocks
  • Obesity
  • Parturient
  • Cesarean
03

In context

Obesity

6,296 studies on the registry are indexed under Obesity; 1,695 are open to participants now.

This study's enrollment of 1,917 is above the median of 135 across 1,283 observational studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Mariah Arif is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Class III Obese parturients undergoing C-section under neuraxial blocks in the operating rooms of Women's Wellness and Research Center from 1 January 2025 to 1 December 2024.

Inclusion criteria

  • Age > or equal to 18 years
  • BMI ≥ 45 kg/m²
  • Gestational age ≥ 28 weeks

Exclusion criteria

Exclusion Criteria:

  • Age \< 18 years
  • BMI \< 45 kg/m²
  • History of venous thromboembolism or arterial disease (e.g., DVT, PE, angina, MI, or stroke)
  • Severe active lung, cardiovascular, renal, or liver disorders; autoimmune disease; or hemoglobinopathies
  • Hereditary or acquired thrombophilia (e.g., Factor V Leiden mutation or antithrombin deficiency)
  • In utero fetal demise (IUFD)
  • Failed operative vaginal delivery
  • Cesarean for the second twin or multiple pregnancies (triplets or higher)
  • IVF pregnancy
  • Intraoperative bleeding>1500mL
  • Emergency cesarean section (Category I)
  • Presence of large uterine fibroid ≥10 cm
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
1,917 participants (actual)
Patient registry
No

Groups and cohorts

  • Class III obese parturient

    Class III obese parturient undergoing cesarean section under neuraxial block

    Procedure: Neuraxial anesthesia

Interventions

  • ProcedureNeuraxial anesthesia

    Single-shot spinal anesthesia

  • ProcedureNeuraxial anesthesia

    Epidural anesthesia

  • ProcedureNeuraxial anesthesia

    Combined spinal-epidural anesthesia

06

What researchers measure

Primary outcomes

  1. Failed neuraxial block

    Determine the occurrence of the conversion to general anesthesia

    Time frame: From onset of block until surgery completion

Secondary outcomes

  1. Maternal adverse events

    Determine the incidence of maternal hypotension, bradycardia, high-spinal (above T1 level), level of blockade higher than T4, post-dural puncture headache

    Time frame: From onset of blockade until surgery completion

  2. Fetal outcomes

    Apgar score

    Time frame: At one and five minutes after birth

07

Study locations

1 site
  • Women's Wellness and Research Center
    Doha, Qatar
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07367386
Lead sponsor
Mariah Arif
Responsible party
Mariah Arif (Resident Physician, Hamad General Hospital) — Sponsor-investigator
First posted
Jan 26, 2026
Start date
Feb 2, 2025
Primary completion
Dec 31, 2025
Completion
Jan 1, 2026
Last update
Jan 27, 2026

Study contacts

Ayten Saracoglu
principal investigator · University of Florida, UF Health, Jacksonville, FL 32209, USA

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion